32:T417,

Aptus Pharma Limited has scheduled a board meeting for Tuesday, March 24, 2026, at its Rajkot office to consider inter alia a proposal for increasing the authorised share capital of the company. The proceedings will also cover the possible consideration and recommendation of a bonus equity issue, subject to approval by the members of the company.

The company has also advised that, in compliance with insider trading regulations, the trading window for designated persons and their immediate relatives will remain closed from March 18, 2026 to March 26, 2026, both days inclusive, in relation to the aforesaid board deliberations. The meeting is intended to enable the board to decide on resolutions requiring member approval and to plan approvals for any related corporate actions.

The notice reiterates the company’s intention to inform the exchange and stakeholders about the outcomes of the board meeting and any ensuing actions, including approvals and timelines for the proposed capital and bonus-related measures.

33:T49b,

Aptus Pharma Limited has announced a significant expansion of its OTC business in Gujarat under its Aptus Well Care Division. The initiative focuses on high-demand consumer categories such as face care, body and skin care, and hair care, led by flagship brands including Timglo, Kerava, and Shirovita. This move aims to broaden the company’s footprint in Gujarat’s growing OTC and personal care market, supported by an expanded field force and distributor network.

The company plans to broaden its product portfolio with new launches across hygiene care, pain relief, and oral care, along with upcoming SKUs like Timglo Detox and Kerava Shea Moisturizer. By enhancing its product lineup and distribution reach, Aptus Pharma seeks to capture a larger market share in the state’s cosmeceutical segment.

Commenting on the development, Managing Director Tejas Hathi said the expansion strengthens Aptus Pharma’s strategic growth in high-demand consumer categories. Aptus Pharma Limited operates across multiple therapeutic areas with a growing distribution network and a focus on specialty and chronic therapy segments as part of its long-term roadmap.

34:T4bb,Aptus Pharma Limited has announced its strategic entry into the urology therapy segment as part of its ongoing business expansion. The company plans to launch a portfolio of products in this segment, including Silodosin, Tamsulosin, and alkalizer formulations. The move is supported by a strong field-sales force and an extensive distribution network, comprising over 150 PLS distributors and sub-distributors across India. The development is expected to contribute to future revenue growth and profitability. The Indian urology market is a fast-growing chronic-therapy segment, currently expanding at approximately 9-10% annually. Aptus Pharma indicates that the new portfolio will enhance its specialty-care capabilities and strengthen its position for sustained growth in the coming years. Management emphasises that this entry aligns with the company’s long-term strategic roadmap to broaden its therapeutic reach. About Aptus Pharma Limited: a growing pharmaceutical company with a broad-based distribution network and a dedicated sales force, increasingly focused on specialty and chronic therapy areas. The company will provide further updates as the portfolio launches and distribution plans evolve.35:T49e,Aptus Pharma Limited has announced the completion of electronic dispatch of the notice of postal ballot dated 24 March 2026, in compliance with applicable laws and SEBI regulations. The newspaper advertisements confirming the dispatch were published in the Financial Express (Ahmedabad English and Gujarati editions) on 27 March 2026. The notice and information pertaining to the postal ballot and e-voting will be hosted on the company's website for shareholder access. The announcement references Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and the

Aptus Pharma Ltd

AI Assistant